- Pfizer promotes 'underappreciated' R&D pipeline
- 1Q EARNINGS: Merck looks to innovation not consolidation
- US Capitol Capsule: Rare disease sector matures; FDA keeping pace?
- All about that (R&D) base: Bristol-Myers and Pfizer 4Q earnings
- PROFILE: AstraZeneca's Mene Pangalos on yin and yang, not believing your own press, and his part in Soriot's vision
- Profile: Fred Hassan, pharma titan, gooseberry picker and secret geography geek